Literature DB >> 33804307

SARS-CoV-2 Is a Culprit for Some, but Not All Acute Ischemic Strokes: A Report from the Multinational COVID-19 Stroke Study Group.

Shima Shahjouei1, Michelle Anyaehie1, Eric Koza2, Georgios Tsivgoulis3, Soheil Naderi4, Ashkan Mowla1,5, Venkatesh Avula1, Alireza Vafaei Sadr6, Durgesh Chaudhary1, Ghasem Farahmand7, Christoph Griessenauer1,8, Mahmoud Reza Azarpazhooh9, Debdipto Misra10, Jiang Li11, Vida Abedi11,12, Ramin Zand1.   

Abstract

BACKGROUND: SARS-CoV-2 infected patients are suggested to have a higher incidence of thrombotic events such as acute ischemic strokes (AIS). This study aimed at exploring vascular comorbidity patterns among SARS-CoV-2 infected patients with subsequent stroke. We also investigated whether the comorbidities and their frequencies under each subclass of TOAST criteria were similar to the AIS population studies prior to the pandemic.
METHODS: This is a report from the Multinational COVID-19 Stroke Study Group. We present an original dataset of SASR-CoV-2 infected patients who had a subsequent stroke recorded through our multicenter prospective study. In addition, we built a dataset of previously reported patients by conducting a systematic literature review. We demonstrated distinct subgroups by clinical risk scoring models and unsupervised machine learning algorithms, including hierarchical K-Means (ML-K) and Spectral clustering (ML-S).
RESULTS: This study included 323 AIS patients from 71 centers in 17 countries from the original dataset and 145 patients reported in the literature. The unsupervised clustering methods suggest a distinct cohort of patients (ML-K: 36% and ML-S: 42%) with no or few comorbidities. These patients were more than 6 years younger than other subgroups and more likely were men (ML-K: 59% and ML-S: 60%). The majority of patients in this subgroup suffered from an embolic-appearing stroke on imaging (ML-K: 83% and ML-S: 85%) and had about 50% risk of large vessel occlusions (ML-K: 50% and ML-S: 53%). In addition, there were two cohorts of patients with large-artery atherosclerosis (ML-K: 30% and ML-S: 43% of patients) and cardioembolic strokes (ML-K: 34% and ML-S: 15%) with consistent comorbidity and imaging patterns. Binominal logistic regression demonstrated that ischemic heart disease (odds ratio (OR), 4.9; 95% confidence interval (CI), 1.6-14.7), atrial fibrillation (OR, 14.0; 95% CI, 4.8-40.8), and active neoplasm (OR, 7.1; 95% CI, 1.4-36.2) were associated with cardioembolic stroke.
CONCLUSIONS: Although a cohort of young and healthy men with cardioembolic and large vessel occlusions can be distinguished using both clinical sub-grouping and unsupervised clustering, stroke in other patients may be explained based on the existing comorbidities.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cerebrovascular disorders; cluster analysis; comorbidity; risk factors; stroke

Year:  2021        PMID: 33804307      PMCID: PMC7957755          DOI: 10.3390/jcm10050931

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

1.  Re: Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.

Authors:  Maryam Bahadori; Ashkan Mowla
Journal:  Am J Emerg Med       Date:  2021-06-01       Impact factor: 4.093

Review 2.  Protein Biomarkers in Blood Reflect the Interrelationships Between Stroke Outcome, Inflammation, Coagulation, Adhesion, Senescence and Cancer.

Authors:  Georg Fuellen; Uwe Walter; Larissa Henze; Jan Böhmert; Daniel Palmer; Soyoung Lee; Clemens A Schmitt; Henrik Rudolf; Axel Kowald
Journal:  Cell Mol Neurobiol       Date:  2022-08-11       Impact factor: 4.231

3.  Ischemic stroke in COVID-19 patients: Mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis.

Authors:  Davide Strambo; Gian Marco De Marchis; Leo H Bonati; Marcel Arnold; Emmanuel Carrera; Santi Galletta; Krassen Nedeltchev; Timo Kahles; Carlo W Cereda; Giovanni Bianco; Georg Kägi; Andreas R Luft; Manuel Bolognese; Lehel-Barna Lakatos; Stephan Salmen; Pamela Correia; Rolf Sturzenegger; Albert Sylvan; Friedrich Medlin; Christian Berger; Florian Lindheimer; Markus Baumgärtner; Ludwig Schelosky; Christophe Bonvin; Marie-Luise Mono; Biljana Rodic; Andrea von Reding; Guido Schwegler; Federico Massini; Alexander A Tarnutzer; Shadi Taheri; Nils Peters; Morin Beyeler; Valerian Altersberger; Stefan T Engelter; Urs Fischer; Patrik Michel
Journal:  Eur J Neurol       Date:  2021-12-09       Impact factor: 6.288

4.  Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative.

Authors:  Payam Sasanejad; Leila Afshar Hezarkhani; Shahram Arsang-Jang; Georgios Tsivgoulis; Abdoreza Ghoreishi; Kristian Barlinn; Jan Rahmig; Mehdi Farhoudi; Elyar Sadeghi Hokmabadi; Afshin Borhani-Haghighi; Payam Sariaslani; Athena Sharifi-Razavi; Kavian Ghandehari; Alireza Khosravi; Craig Smith; Yongchai Nilanont; Yama Akbari; Thanh N Nguyen; Anna Bersano; Nawaf Yassi; Takeshi Yoshimoto; Simona Lattanzi; Animesh Gupta; Ramin Zand; Shahram Rafie; Seyede Pourandokht Mousavian; Mohammad Reza Shahsavaripour; Shahram Amini; Saltanat U Kamenova; Aida Kondybayeva; Murat Zhanuzakov; Elizabeth M Macri; Christa O'Hana S Nobleza; Sean Ruland; Anna M Cervantes-Arslanian; Masoom J Desai; Annemarei Ranta; Amir Moghadam Ahmadi; Mahtab Rostamihosseinkhani; Razieh Foroughi; Etrat Hooshmandi; Fahimeh H Akhoundi; Ashfaq Shuaib; David S Liebeskind; James Siegler; Jose G Romano; Stephan A Mayer; Reza Bavarsad Shahripour; Babak Zamani; Amadene Woolsey; Yasaman Fazli; Khazaei Mojtaba; Christian F Isaac; Jose Biller; Mario Di Napoli; M Reza Azarpazhooh
Journal:  J Stroke Cerebrovasc Dis       Date:  2021-09-20       Impact factor: 2.677

Review 5.  Comprehensive Review on Neuro-COVID-19 Pathophysiology and Clinical Consequences.

Authors:  Helia Jafari Khaljiri; Monire Jamalkhah; Ali Amini Harandi; Hossein Pakdaman; Milad Moradi; Ashkan Mowla
Journal:  Neurotox Res       Date:  2021-06-25       Impact factor: 3.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.